Tasveer Khawaja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tasveer Khawaja has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Shilpkumar Arora
Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas; Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, Ohio
5 shared publicationsRahul Jaswaney
Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, Ohio; Temple University Hospital Heart and Vascular Center, Philadelphia, Pennsylvania
3 shared publications- Sadeer Al-Kindi
DeBakey Heart and Vascular Center, Houston Methodist Hospital , Houston, TX
3 shared publications - Mehdi H. Shishehbor
University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH, USA
2 shared publications Mohammed Najeeb Osman
Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, Ohio
2 shared publications- Monil Majmundar
Department of Cardiovascular Medicine University of Kansas Medical Center Kansas City KS USA
2 shared publications
Latest Publications
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (1) , e013338
Air Pollution and Exposomic Impacts on Heart Failure
Air pollution is a major global environmental health threat and the leading environmental risk factor contributing to cardiovascular morbidity and mortality. Emerging evidence increasingly implicates air pollution as a critical, modifiable driver in the pathogenesis, progression, and prognosis of heart failure. Air pollution is increasingly recognized as part of the exposome—a complex interplay of environmental, social, and behavioral exposures accumulated across the life course. In this review, we synthesize experimental data demonstrating mechanistic links between air pollution and heart failure, along with growing experimental, clinical, and epidemiological evidence connecting both short- and long-term air pollution exposure with increased risk of heart failure progression across heart failure stages. We further examine how air pollution interacts with other exposomic risk domains—such as the social exposome, built environment, and access to greenery—compounding vulnerability in marginalized and underserved populations. The review will also summarize current approaches to communicate air pollution risk and propose practical strategies for both individuals and healthcare systems to mitigate its cardiovascular impact. Finally, we present a clinical framework for assessing and managing air pollution exposure in patients with heart failure, emphasizing the need for targeted risk stratification and the development of context-specific mitigation interventions.
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (1) , e013338
Air Pollution and Exposomic Impacts on Heart Failure
Air pollution is a major global environmental health threat and the leading environmental risk factor contributing to cardiovascular morbidity and mortality. Emerging evidence increasingly implicates air pollution as a critical, modifiable driver in the pathogenesis, progression, and prognosis of heart failure. Air pollution is increasingly recognized as part of the exposome—a complex interplay of environmental, social, and behavioral exposures accumulated across the life course. In this review, we synthesize experimental data demonstrating mechanistic links between air pollution and heart failure, along with growing experimental, clinical, and epidemiological evidence connecting both short- and long-term air pollution exposure with increased risk of heart failure progression across heart failure stages. We further examine how air pollution interacts with other exposomic risk domains—such as the social exposome, built environment, and access to greenery—compounding vulnerability in marginalized and underserved populations. The review will also summarize current approaches to communicate air pollution risk and propose practical strategies for both individuals and healthcare systems to mitigate its cardiovascular impact. Finally, we present a clinical framework for assessing and managing air pollution exposure in patients with heart failure, emphasizing the need for targeted risk stratification and the development of context-specific mitigation interventions.
- 14 October 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 207, 470-478
Outcomes With Intravascular Ultrasound and Optical Coherence Tomography Guidance in Percutaneous Coronary Intervention
- 14 October 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 207, 470-478
Outcomes With Intravascular Ultrasound and Optical Coherence Tomography Guidance in Percutaneous Coronary Intervention
- 6 October 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 208, 13-15
Prognostic Value of Pulmonary Artery Oxygen Saturation in Pulmonary Embolism Requiring Endovascular Intervention
- 6 October 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 208, 13-15
Prognostic Value of Pulmonary Artery Oxygen Saturation in Pulmonary Embolism Requiring Endovascular Intervention
- Open Access
- 1 August 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (15) , e029738
Causes and Predictors of 30‐Day Readmission in Patients With COVID‐19 and ST‐Segment–Elevation Myocardial Infarction in the United States: A Nationwide Readmission Database Analysis
Background: Rates, causes, and predictors of readmission in patients with ST‐segment–elevation myocardial infarction (STEMI) during COVID‐19 pandemic are unknown. Methods and Results: All hospitalizations for STEMI were selected from the US Nationwide Readmissions Database 2020 and were stratified by the presence of COVID‐19. Primary outcome was 30‐day readmission. Multivariable hierarchical generalized logistic regression analysis was performed to compare 30‐day readmission between patients with STEMI with and without COVID‐19 and to identify the predictors of 30‐day readmissions in patients with STEMI and COVID‐19. The rate of 30‐day all‐cause readmission was 11.4% in patients with STEMI who had COVID‐19 and 10.6% in those without COVID‐19, with the adjusted odds ratio (OR) not being significantly different between the two groups (OR, 0.88 [95% CI, 0.73–1.07], P =0.200). Of all 30‐day readmissions in patients with STEMI and COVID‐19, 41% were for cardiac causes. Among the cardiac causes, 56% were secondary to acute coronary syndrome, while among the noncardiac causes, infections were the most prevalent. Among the causes of 30‐day readmissions, infectious causes were significantly higher for patients with STEMI who had COVID‐19 compared with those without COVID‐19 (29.9% versus 11.3%, P =0.001). In a multivariable model, congestive heart failure, chronic kidney disease, low median household income, and length of stay ≥5 days were found to be associated with an increased risk of 30‐day readmission. Conclusions: Post‐STEMI, 30‐day readmission rates were similar between patients with and without COVID‐19. Cardiac causes were the most common causes for 30‐day readmissions, and infections were the most prevalent noncardiac causes.
- 1 August 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (15) , e029738
Open AccessCauses and Predictors of 30‐Day Readmission in Patients With COVID‐19 and ST‐Segment–Elevation Myocardial Infarction in the United States: A Nationwide Readmission Database Analysis
Background: Rates, causes, and predictors of readmission in patients with ST‐segment–elevation myocardial infarction (STEMI) during COVID‐19 pandemic are unknown. Methods and Results: All hospitalizations for STEMI were selected from the US Nationwide Readmissions Database 2020 and were stratified by the presence of COVID‐19. Primary outcome was 30‐day readmission. Multivariable hierarchical generalized logistic regression analysis was performed to compare 30‐day readmission between patients with STEMI with and without COVID‐19 and to identify the predictors of 30‐day readmissions in patients with STEMI and COVID‐19. The rate of 30‐day all‐cause readmission was 11.4% in patients with STEMI who had COVID‐19 and 10.6% in those without COVID‐19, with the adjusted odds ratio (OR) not being significantly different between the two groups (OR, 0.88 [95% CI, 0.73–1.07], P =0.200). Of all 30‐day readmissions in patients with STEMI and COVID‐19, 41% were for cardiac causes. Among the cardiac causes, 56% were secondary to acute coronary syndrome, while among the noncardiac causes, infections were the most prevalent. Among the causes of 30‐day readmissions, infectious causes were significantly higher for patients with STEMI who had COVID‐19 compared with those without COVID‐19 (29.9% versus 11.3%, P =0.001). In a multivariable model, congestive heart failure, chronic kidney disease, low median household income, and length of stay ≥5 days were found to be associated with an increased risk of 30‐day readmission. Conclusions: Post‐STEMI, 30‐day readmission rates were similar between patients with and without COVID‐19. Cardiac causes were the most common causes for 30‐day readmissions, and infections were the most prevalent noncardiac causes.
- Open Access
- 5 May 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (5)
Surgical and transcatheter left atrial appendage closure in patients with atrial fibrillation and hypertrophic cardiomyopathy
Patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF) are at increased stroke risk in comparison to those with non-valvular AF not affected by HCM. To investigate the role of left atrial appendage closure (LAAC) in patients with HCM and AF. We identified patients with HCM and AF using the National Readmission Dataset. Patients were stratified based on LAAC status. The primary efficacy outcome was a composite of ischaemic and haemorrhagic stroke, TIA, and all-cause mortality. The primary safety outcome was a composite of major bleeding and pericardial complications. Patients were matched using inverse probability of treatment weighting. Cox-proportional hazard regression was applied to calculate the hazard ratio (HR) with a 95% confidence interval (CI) on matched cohorts. We identified 71 980 patients with HCM and AF. 1351 (1.9%) patients underwent LAAC. Two hundred and eighty-seven (21.2%) underwent transcatheter LAAC. LAAC was associated with a lower risk of the primary efficacy outcome (2.5% vs. 5.4%, HR: 0.38; 95% CI: 0.17–0.88; P = 0.024), the primary safety outcome (2.9% vs. 6.8%, HR: 0.39; 95% CI: 0.23–0.66, P = 0.001), and reduced major bleeding. The LAAC group trended towards a lower risk of ischaemic stroke and all-cause mortality. Surgical and transcatheter LAAC was associated with a lower risk of haemorrhagic stroke and major bleeding.
- 5 May 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (5)
Open AccessSurgical and transcatheter left atrial appendage closure in patients with atrial fibrillation and hypertrophic cardiomyopathy
Patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF) are at increased stroke risk in comparison to those with non-valvular AF not affected by HCM. To investigate the role of left atrial appendage closure (LAAC) in patients with HCM and AF. We identified patients with HCM and AF using the National Readmission Dataset. Patients were stratified based on LAAC status. The primary efficacy outcome was a composite of ischaemic and haemorrhagic stroke, TIA, and all-cause mortality. The primary safety outcome was a composite of major bleeding and pericardial complications. Patients were matched using inverse probability of treatment weighting. Cox-proportional hazard regression was applied to calculate the hazard ratio (HR) with a 95% confidence interval (CI) on matched cohorts. We identified 71 980 patients with HCM and AF. 1351 (1.9%) patients underwent LAAC. Two hundred and eighty-seven (21.2%) underwent transcatheter LAAC. LAAC was associated with a lower risk of the primary efficacy outcome (2.5% vs. 5.4%, HR: 0.38; 95% CI: 0.17–0.88; P = 0.024), the primary safety outcome (2.9% vs. 6.8%, HR: 0.39; 95% CI: 0.23–0.66, P = 0.001), and reduced major bleeding. The LAAC group trended towards a lower risk of ischaemic stroke and all-cause mortality. Surgical and transcatheter LAAC was associated with a lower risk of haemorrhagic stroke and major bleeding.
- Open Access
- 30 August 2022
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 12, 100378
Prevalence of thoracic aortic aneurysm in patients referred for no/low-charge coronary artery calcium scoring: Insights from the CLARIFY registry
- 30 August 2022
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 12, 100378
Open AccessPrevalence of thoracic aortic aneurysm in patients referred for no/low-charge coronary artery calcium scoring: Insights from the CLARIFY registry
- 18 May 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 175, 44-51
Timing of Repair in Postinfarction Ventricular Septal Defect
- 18 May 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 175, 44-51
Timing of Repair in Postinfarction Ventricular Septal Defect
- Open Access
- 26 April 2022
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 16
Role of Coronary CT Angiography in the Evaluation of Acute Chest Pain and Suspected or Confirmed Acute Coronary Syndrome
Advances in CT technology have resulted in improved imaging of the coronary anatomy in patients with stable coronary artery disease, using coronary CT angiography (CCTA). Recent data suggest that CCTA may play a role in higher risk patients, such as those evaluated in the emergency room with acute chest pain. Data thus far support the use of CCTA in low-risk patients with acute chest pain. Recent literature suggests that CCTA may play a role in the risk stratification of selected intermediate-risk patients. In this review, the authors discuss the emerging role of CCTA in higher risk patients, such as those with suspected or confirmed acute coronary syndrome (ACS). The excellent accuracy of CCTA in detecting obstructive coronary artery disease in patients with ACS is detailed, along with a highlighting of the safety of using CCTA in this setting. The authors also discuss the role for CCTA atheromatous plaque characterization, which is being increasingly recognized as an important predictor of clinical outcomes.
- 26 April 2022
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 16
Open AccessRole of Coronary CT Angiography in the Evaluation of Acute Chest Pain and Suspected or Confirmed Acute Coronary Syndrome
Advances in CT technology have resulted in improved imaging of the coronary anatomy in patients with stable coronary artery disease, using coronary CT angiography (CCTA). Recent data suggest that CCTA may play a role in higher risk patients, such as those evaluated in the emergency room with acute chest pain. Data thus far support the use of CCTA in low-risk patients with acute chest pain. Recent literature suggests that CCTA may play a role in the risk stratification of selected intermediate-risk patients. In this review, the authors discuss the emerging role of CCTA in higher risk patients, such as those with suspected or confirmed acute coronary syndrome (ACS). The excellent accuracy of CCTA in detecting obstructive coronary artery disease in patients with ACS is detailed, along with a highlighting of the safety of using CCTA in this setting. The authors also discuss the role for CCTA atheromatous plaque characterization, which is being increasingly recognized as an important predictor of clinical outcomes.
- Open Access
- 3 June 2021
- Published by Springer Nature in Research Square
The Impact of SARS-COV-2 Variants on Vaccine Efficacy Amongst Healthcare Workers During India’s Second Wave
Despite a growing sense of normalcy in many Western nations, another wave of the COVID-19 pandemic has spread rapidly through the Indian subcontinent.To improve our understanding of the crisis in India and the impact it is having on healthcare workers, we administered an electronic poll to healthcare workers in India.A total of 199 healthcare workers responded to the survey, the majority of whom were physicians. Of all respondents, 177 had received at least one dose of a COVID-19 vaccine. Of those vaccinated, 14 respondents (7.9%) received the Covaxin® (Bharat Biotech) vaccine, while the remaining 163 respondents (92.1%) received the Covishield® (Oxford-AstraZeneca) vaccine. Of the 177 respondents who received a dose of a COVID-19 vaccine, 76 (43%) acquired COVID-19 after vaccination, of which 88% had symptomatic infections. The protection offered by vaccination against new strains of SARS-CoV2 is a central question to which there remains an unclear answer.No external sources of funding were used.
- 3 June 2021
- Published by Springer Nature in Research Square
Open AccessThe Impact of SARS-COV-2 Variants on Vaccine Efficacy Amongst Healthcare Workers During India’s Second Wave
Despite a growing sense of normalcy in many Western nations, another wave of the COVID-19 pandemic has spread rapidly through the Indian subcontinent.To improve our understanding of the crisis in India and the impact it is having on healthcare workers, we administered an electronic poll to healthcare workers in India.A total of 199 healthcare workers responded to the survey, the majority of whom were physicians. Of all respondents, 177 had received at least one dose of a COVID-19 vaccine. Of those vaccinated, 14 respondents (7.9%) received the Covaxin® (Bharat Biotech) vaccine, while the remaining 163 respondents (92.1%) received the Covishield® (Oxford-AstraZeneca) vaccine. Of the 177 respondents who received a dose of a COVID-19 vaccine, 76 (43%) acquired COVID-19 after vaccination, of which 88% had symptomatic infections. The protection offered by vaccination against new strains of SARS-CoV2 is a central question to which there remains an unclear answer.No external sources of funding were used.